Evidence map›Paper›PMID 34193755›Full record

Trial reportJournal of clinical and experimental hematopathology : JCEH2021

A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphoma.

Kazunori Ohnishi, Ken Ohmachi, Kiyoshi Ando, Kazuhito Yamamoto, Tatsuya Ito, Mitsune Tanimoto, Kaneyuki Ohbayashi, Kazuma Ohyashiki, Kunihiro Tsukasaki, Kensuke Naito and 7 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical and experimental hematopathology : JCEH, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

Kazunori OhnishiDepartment of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Ken OhmachiDepartment of Hematology and Oncology, Tokai University, Isehara, Japan.
Kiyoshi AndoDepartment of Hematology and Oncology, Tokai University, Isehara, Japan.
Kazuhito YamamotoDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Tatsuya ItoDepartment of Hematology, Anjo Kosei Hospital, Anjo, Japan.
Mitsune TanimotoDepartment of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Kaneyuki OhbayashiDepartment of Hematology, Toyota Memorial Hospital, Toyota, Japan.
Kazuma OhyashikiDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Kunihiro TsukasakiDepartment of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Kensuke NaitoDepartment of Hematology, Hamamatsu Medical Center, Hamamatsu, Japan.
Takayo SuzukiDepartment of Hematology, Shiga General Hospital, Moriyama, Japan.
Takaaki OnoDepartment of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Koichi MiyamuraHematology, Japanese Red Cross Nagoya First Hospital, Nagoya, Japan.
Yoshitoyo KagamiDepartment of Hematology, Toyota Kosei Hospital, Toyota, Japan.
Tomohiro KinoshitaDepartment of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan.
Tomomitsu HottaNational Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Michinori OguraDepartment of Hematology and Oncology, Japanese Red Cross Nagoya Daini Hospital, Nagoya, Japan.
Aichi Cancer Center · JPHamamatsu University School of Medicine · JPTokai University · JPAnjo Kosei Hospital · JPHamamatsu Medical Center · JPJapanese Red Cross Nagoya Daini Hospital · JPNagasaki University · JPNational Hospital Organization · JPOkayama University Hospital · JPShiga Medical Center · JPTokyo Medical University · JPToyota Kosei Hospital · JPToyota Memorial Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The optimal combined chemotherapy regimen with rituximab has yet to be established for elderly patients with advanced-stage indolent B-cell lymphoma (B-NHL). A multicenter study was performed to evaluate the efficacy and toxicity of R-THP-COP therapy in elderly patients (aged 70-79 years) with newly diagnosed advanced-stage indolent B-NHL using the complete response rate (%CR) as the primary endpoint. Patients with newly diagnosed, clinical stage III/IV, indolent B-NHL, aged 70-79 years, with a performance status of 0-2 were eligible for this study. R-THP-COP consists of 375 mg/m

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDoxorubicinHumansLymphoma, B-CellMaleNeoplasm GradingNeoplasm StagingPrednisoloneRituximabTreatment OutcomeVincristineCyclophosphamideDoxorubicinpirarubicinPrednisoloneRituximabVincristineelderly patientsIndolent B-cell lymphomaR-THP-COP

Identifiers

PMID34193755
PMCPMC8519245
OpenAlexW3177369227

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.